IRCT2017031333044N1已完成2 期
Efficacy of Pirfenidone versus placebo in Idiopathic Pulmonary Fibrosis progression: a randomize clinical trial
Vice chancellor for research, Shahid Behesti University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •1-Confirmed Idiopathic Pulmonary Fibrosis with lung biopsy
- •2-UIP view in lung HRCT with unknown cause base of ATS-ERS criteria
- •3-Agreement to participate in this study
- •Exclusion criteria:
- •1-Suffering from connective tissue disease
- •2-occupational exposure to substances that cause lung fibrosis
- •3-close contact with animals
- •4-Deny to participate in this study
排除标准
- 未提供
研究者
相似试验
尚未招募
Unknown
sefulness of a new medicine -pirfenidone in oral fibrosis due to Arecanut and tobacco useCTRI/2023/04/051723Indian Council of Medical Research
已完成
不适用
Observational study of the effect of Pirfenidone on cough in patients with idiopathic pulmonary fibrosis.scarring of the lung10024967Idiopathic pulmonary fibrosisNL-OMON41593Erasmus MC, Universitair Medisch Centrum Rotterdam35
进行中（未招募）
1 期
Standard-armed controlled study to assess the impact of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)1.Fibrotic NSIP., 2.Chronic Hypersensitivity Pneumonitis 3. Lung fibrosis associated with collagen / vascular diseases, 4.Asbestos-induced lung fibrosisMedDRA version: 20.0Level: LLTClassification code 10022612Term: Interstitial lung fibrosisSystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10035754Term: Pneumonitis hypersensitivitySystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10025088Term: Lung fibrosisSystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10022617Term: Interstitial pneumoniaSystem Organ Class: 100000004855EUCTR2014-000861-32-DEJustus Liebig Universität Giessen374
进行中（未招募）
2 期
Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) -A randomized, double-blind, placebo-controlled, parallel group,multi-center, phase II trialJ84.1J68.4Other interstitial pulmonary diseases with fibrosisChronic respiratory conditions due to chemicals, gases, fumes and vapoursDRKS00009822Justus-Liebig Universität Giessen127
尚未招募
不适用
Comparison of providone iodine and chlorhexidine as a mouth rinse before cleaning treatment to reduce the bacterial count during treatmentCTRI/2021/10/037528askath sabana